REBECCA ROCHFORD BUCKLEY: Open Payments
NPI 1306613906 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,697 in 165 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $2,638 · 2025 $3,697
Food & beverage: $3,693Education: $4
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $506 |
| Axsome Therapeutics, Inc. | 8 | $352 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $335 |
| ABBVIE INC. | 14 | $293 |
| Teva Pharmaceuticals USA, Inc. | 21 | $262 |
| Vanda Pharmaceuticals Inc. | 9 | $258 |
| Alkermes, Inc. | 13 | $255 |
| Otsuka America Pharmaceutical, Inc. | 11 | $255 |
| Bausch Health US, LLC | 10 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $198 |
Products named: INGREZZA, Auvelity, CAPLYTA, REXULTI, VRAYLAR, HETLIOZ, ARISTADA, APLENZIN.
Industry payments across FL — which companies pay providers there.
